Seroprevalence of COVID-19
- Conditions
- Covid19
- Interventions
- Diagnostic Test: laboratory test
- Registration Number
- NCT04941053
- Lead Sponsor
- Sohag University
- Brief Summary
Coronavirus disease pandemic has been started in late 2019. Since this date, the number of cases has been increased reaching 32.7 million cases worldwide in 27 September, 2020. . Herd immunity is achieved when enough people become immune to a virus to stop its spread. Around 70% to 90% of a population needs to be immune to protect the uninfected. In A Spanish study of more than 30,000 people estimates that around just 5% of the Spanish population has developed antibodies
- Detailed Description
Aims of work:
A cross-sectional study to detect the seroprevalence to COVID 19 in chronic hemodialysis patients and compare it with the COVID 19 seroprevalence in healthy control in Sohag governorate Egypt
Methods:
After taken informed consent according to Sohag University Ethical Committee A questionnaire on coronavirus symptoms will be asked including epidemiological characters and history of previous COVID 19 infection and infection control measures to prevent it
5 ml of the blood sample will be taken for IgG antibodies testing with a chemiluminescent microparticle immunoassay.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
- patient accept to participate
- vaccinated people
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description group 1 chronic haemodialysis patients laboratory test seroprevalnce of COVID 19 healthy control laboratory test seroprevalnce of COVID 19
- Primary Outcome Measures
Name Time Method seroprevalnce 3-6-2021 to 30-8-2021 antibody measurement
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Sohag University
🇪🇬Sohag, Egypt